According to the bylaws, the PIF Board is composed of 12 members. The term of each member is three years, and one third of the members will retire in turn.

Summoned by the Board Chairman or Vice Chairman, the Board will convene once a month on average, generally about 10 times a year. The Board elects the Chairman and two Vice Chairmen among its members. Together with the Managing Director, the Chair constitutes the Working Committee. As decided by the Board, the Working Committee can also include other members.

All the issues to be resolved by the Board are prepared by the Working Committee.

Chairman: 
Mr Ove Uljas, Pfizer Oy*

I Deputy Chairman:
Mr Ilpo Tolonen, MSD Finland Oy*

II Deputy Chairman:
Mr Pekka Kaivola, Orion Oyj Orion Pharma*

Other members:
Mr Markku Hämäläinen
Mr Leif Jokinen, Oy H. Lundbeck Ab
Mr Jyrki Liljeroos, Santen Oy
Mr Harry Råstedt, GlaxoSmithKline Oy
Mr Ari Rönkä, Ferring Lääkkeet Oy
Mr Markku Santonen, Amgen AB
Mr Lasse Savonen, AstraZeneca Oy
Mr Antti Viitanen, Novartis Finland Oy*

Secretary:
Ms Suvi-Anne Siimes, PIF

* Member of the Working Committee